Drug
Ly2801653
Ly2801653: highest development phase Phase 1, developed by Eli Lilly. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Eli Lilly
Trials
| Drug | Phase | Indication |
|---|---|---|
| LY2801653 NCT01285037 | Phase 1 | Cancer |
Latest
No recent events.
Follow Ly2801653 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.